The Korea Drug Development Fund (KDDF) is the largest public financer of drug R&D in Korea, investing over $150 million annually to enhance the competitiveness of the local biopharma sector. Since its inception, KDDF has supported 345 projects, 172 of which focus on oncology, emphasizing novel targets and innovative drug modalities. Three notable companies funded include:
-
PimedBio: Developing PMB212, a first-in-class cancer stemness blocker showing promise in treating various cancers with a strong safety profile.
-
AbTis: Focused on antibody-drug conjugate (ADC) technology, its lead candidate AT-211 targets CLDN18.2 in gastric cancer, with FDA IND approval expected soon.
-
CellBion: A leader in radioligand therapies, currently advancing Lu-177-DGUL for prostate cancer, which is in phase 2 trials and has received orphan drug designation in Korea.
KDDF is enhancing global drug development collaboration and success rates in the Korean biopharma landscape.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.nature.com/articles/d43747-024-00020-y
